Louise Perkins
Showing 1–3 of 3 transcripts.
- Milken Institute56 min
Preserving the Promise of Cancer Immunotherapy
Louise Perkins, Pablo Legorreta, Johanna Mercier, Jill O'Donnell-Tormey, Antoni Ribas, Greg Simon
The Melanoma Research Alliance, alongside the Biden Cancer Initiative and L'Oréal Paris, is addressing the persistent 50% non-response rate to current immunotherapies by promoting platform trials and data-sharing networks to eliminate redundant "Me Too" drug development. While recent clinical advances have extended survival for metastatic patients to a decade or more, experts emphasize the urgent need to de-risk academic discoveries through nonprofit incubators and standardized liquid biopsies to prevent early-stage cancer from progressing to terminal stages. Strategic recommendations from industry leaders and researchers prioritize patient-centric trial design and sustained basic science funding to ensure these breakthroughs reach community oncologists and avoid investment withdrawal from other critical therapeutic classes.
- Milken Institute1h 4m
Breakthrough Medicine: Will Finding a Cure Be Just the Start of Saving Lives?
Louise Perkins, Jill DeSimone, Omid Hamid, Daniel Hilferty, Gideon Bollig, Wyatt Decker
Led by the Melanoma Research Alliance and Mayo Clinic, this event synthesizes breakthroughs in immunotherapy and genomic medicine that are transforming late-stage melanoma from a fatal diagnosis into a manageable chronic condition. Panelists addressed critical barriers to patient access, including high drug costs, reimbursement lags, and the need for updated clinical training, while proposing public-private partnerships to streamline regulatory pathways. The discussion concluded with a strategic vision to scale personalized care to millions of patients, aligning incentives across payers, providers, and researchers to extend these life-saving advances to broader diseases.
- Milken Institute1h 1m
Mobilizing the Immune System in the Battle Against Cancer
Arie Belldegrun, Michael Giordano, Jeff Rowbottom, Suzanne Topalian, Louise Perkins
Hosted by the Melanoma Research Alliance, the "Mobilizing the Immune System in the Battle Against Cancer" panel examines the critical transition from traditional chemotherapy to innovative immunotherapies that are driving unprecedented survival rates for melanoma and other malignancies. Experts detail how genetic engineering and checkpoint inhibitors have enabled durable remissions for late-stage patients while highlighting the urgent need for new regulatory frameworks and increased nonprofit funding to accelerate the development of super-personalized combination treatments. The discussion underscores a projected five-year transformation in oncology, emphasizing that converging scientific breakthroughs and global stakeholder collaboration are essential to address rising cancer mortality and realize a potential cure for previously resistant diseases.